Mayukh Sukhatme Sells 172,899 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 172,899 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $37.17, for a total value of $6,426,655.83. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at approximately $692,504,568.63. This represents a 0.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The shares were sold at an average price of $37.30, for a total transaction of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Stock Down 1.5%

Shares of ROIV stock opened at $36.30 on Friday. The stock has a market cap of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12. Roivant Sciences Ltd. has a 52-week low of $11.60 and a 52-week high of $37.97. The business has a 50-day simple moving average of $34.61 and a 200-day simple moving average of $30.43.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Sell-side analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ROIV shares. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright raised their price objective on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after buying an additional 34,341 shares during the last quarter. American Century Companies Inc. raised its position in shares of Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after buying an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after buying an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in shares of Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.